<DOC>
	<DOCNO>NCT02958033</DOCNO>
	<brief_summary>In study , eligible breast cancer patient randomize divide two group . study group receive accelerate hypo-fractioned whole breast irradiation concurrent boost tumor bed ( WBI 2.5Gy x18 SIB 2.88Gy x18 ) control group receive conventional fractioned whole breast irradiation concurrent boost tumor bed ( WBI 1.8Gy x28 SIB 2.15Gy x28 ) . All radiotherapy deliver external beam-intensity modulate radiotherapy . purpose study ass whether accelerated hypo-fractioned non-inferior conventional fractionate radiotherapy . The outcomes evaluation include acute toxicity , late toxicity include breast fibrosis cardiac disease , cosmetic outcome , local control survival outcome .</brief_summary>
	<brief_title>Shandong Cancer Hospital Affiliated Shandong University</brief_title>
	<detailed_description />
	<criteria>1 . Female patient breast conserve surgery 2. age ≥ 18 ≤ 65 year 3. histological diagnosis invasive carcinoma breast 4. pathological stage T12N01M0 5. multidisciplinary decision adjuvant WBI boost tumor bed 6. informed consent obtain , sign date specific protocol procedure 1. patient treat Mastectomy 2 . Need lymph node irradiation 3. positive close ( ≤ 1 mm ) surgical margin 4. treat neoadjuvant chemotherapy surgery 5 . Bilateral malignancy breast ( synchronous metachronous ) 6 . Pregnant breastfeed 7 . Mental condition render patient unable understand nature , scope possible consequence study 8 . Patient unlikely comply protocol ; i.e . uncooperative attitude , inability return followup visit , unlikely complete study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>